The single chain fragment variable (scFv) from our anti-MUC1* antibody is the targeting head for anti-MUC1* CARs (chimeric antigen receptor) for T cell immunotherapy. We have also developed proprietary CAR constructs with clean IP. Together this gives us complete CAR T therapeutics.
Our CAR T therapeutics will attack solid tumors that are MUC1* positive. This represents approximately 80% of all cancers, including 96-98% of breast cancers and very high percentages of patients with ovarian and pancreatic cancers and melanomas.
No other CAR T company has a cancer specific target for solid tumor – their successes have been limited to blood cancers.
Minerva is aiming to be in clinical trials in 2017 with an initial focus on patients with advanced breast and ovarian cancers.